The FDA said its investigation shows that only the two recalled lots were potentially contaminated, and no adverse event reports have been received.
The agency said that administering dexmedetomidine with trace amounts of lidocaine to a patient could cause anaphylaxis, which can be life-threatening.
Read the FDA’s full news release here.
More articles on pharmacy:
NIH updates remdesivir treatment guidelines
J&J to start human trials for COVID-19 vaccine this week
Growing number of polls find Americans hesitant about getting a future COVID-19 vaccine
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
